The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings. Giving obese children weight-loss ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Experts say weight management drugs have created an unsustainable surge in health care spending, with some insurance ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more effective than getting weight loss surgery.